Immune Checkpoint Inhibitors Market to 2023 (25.6% CAGR Expected) Top Player Profiles – AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

The global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is projected to reach $65,427 million by 2025, registering a CAGR of 25.6% from 2018 to 2025.

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1).

Get Sample Copy of this Report @ https://www.researchbeam.com/immune-check-point-inhibitors-market/request-sample?utm_source=Anil&utm_medium=OPR

Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in incidence of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth. 

The global immune checkpoint inhibitor market is segmented based on type, application, and region. On the basis of type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The applications covered in the study include lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Type

CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor
By Application

Lung Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Others
Get a discount on this research report @ https://www.researchbeam.com/immune-check-point-inhibitors-market/purchase-enquiry?utm_source=Anil&utm_medium=OPR

LIST OF KEY PLAYERS PROFILED IN THE REPORT : AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, Pfizer Inc.

Table of Content:

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top player positioning

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Increase in incidence of cancer across the globe

3.3.1.2. Surge in global geriatric population

3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors

3.3.1.4. Surge in healthcare expenditure worldwide

3.3.2. Restraint

3.3.2.1. Higher cost of immune checkpoint inhibitors

3.3.3. Opportunities

3.3.3.1. Increase in number of pipeline drugs

3.3.3.2. Growth opportunities in the emerging markets

3.3.4. Impact analyses

3.4. Clinical trials

3.5. Pipeline analyses

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. CTLA-4 inhibitor

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast

4.3. PD-1 inhibitor

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast

4.4. PD-L1 inhibitor

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung cancer

5.2.1. Market size and forecast

5.3. Bladder cancer

5.3.1. Market size and forecast

5.4. Melanoma

5.4.1. Market size and forecast

5.5. Hodgkin lymphoma

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

Enquiry before Buy @ https://www.researchbeam.com/immune-check-point-inhibitors-market/enquire-about-report?utm_source=Anil&utm_medium=OPR

About Us:

Research Beam is a high end and wide online market for market research reports that contain detailed and rational market research. Research Beam is a one stop report destination that offers clients well drafted and accurately analyzed report with insightful data.

Global Head Quarters
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
+1 (800) 910-6452
help@researchbeam.com

This release was published on openPR.